Latest news with #BRL
Time of India
21-05-2025
- Entertainment
- Time of India
Red Dead games get surprise price hike amid next-gen patch and GTA 6 pricing rumors
Source: Rockstar Games Rockstar Games has quietly hiked the digital prices of Red Dead Redemption and Red Dead Redemption 2 in some regions, fueling gossip about the company's overall pricing strategy. With rumors circulating over a next-gen patch for RDR2 and growing expectations for GTA 6, fans are starting to wonder if Rockstar is positioning itself for even higher prices on subsequent releases. Red Dead prices surge unexpectedly across several regions The initial indication of the price increase was seen in Brazil, where Red Dead Redemption (2010) rose from 89 BRL ($16) to 149 BRL ($26), and Red Dead Redemption 2 escalated from 250 BRL to 300 BRL. This is a major development for 15 and 7-year-old games, respectively. Increases have also been noticed in the UK, where RDR2 increased from £54.99 to £59.99, and RDR1 rose from £24.99 to £29.99. Other nations, such as Chile and the Czech Republic, also experienced regional price changes. The U.S. and most other regions are still safe for the meantime, though. What's interesting is that the PC versions of RDR2 on platforms such as Steam, Epic Games Store, and Rockstar's launcher have kept its price low, now only $15 in some instances, its all-time lowest. Speculation mounts regarding Rockstar's pricing policy and GTA 6 Although Rockstar and parent publisher Take-Two have not offered an official statement, industry observers are attributing the changes to an overarching trend in pricing. Nintendo recently set Mario Kart World at $80 for the next Switch 2, and Xbox will do the same with certain first-party titles. Fans now worry GTA 6 may be launched at or near this $80 figure. The Red Dead price increases also come at the same time as a speculated next-gen patch for RDR2, which implies that Rockstar might be setting the stage for a high-end re-release, albeit one similar in nature to GTA V. And with RDR2 leading PlayStation download lists and hitting 74 million units sold, Rockstar might just be profiting from long-term popularity. Even though there has been no official release, Rockstar's under-the-table price adjustments are doing the rounds. Whether setting the stage for a next-gen refresh or trying waters ahead of GTA 6's eventual price release, this is one thing that is certain: the price of being a Rockstar enthusiast may be increasing. Also Read: Ex-Rockstar Games dev Mike York reflects on the GTA 6 delay Get IPL 2025 match schedules , squads , points table , and live scores for CSK , MI , RCB , KKR , SRH , LSG , DC , GT , PBKS , and RR . Check the latest IPL Orange Cap and Purple Cap standings.
Business Standard
21-05-2025
- Business
- Business Standard
Torrent Pharma gains as Q4 PAT rises 11% YoY to Rs 498 cr; recommends final dividend of Rs 6/sh
Torrent Pharmaceuticals added 1.53% to Rs 3,292.95 after the company's consolidated net profit increased 10.91% to Rs 498 crore in Q4 FY25 as against Rs 449 crore posted in Q4 FY24. Total revenue from operations grew 7.79% year on year (YoY) to Rs 2,959 crore in the quarter ended 31 March 2025. Profit before tax stood at Rs 665 crore in March 2025 quarter, up 5.38% from Rs 631 crore posted in same quarter last year. Operating EBITDA stood at Rs 964 crore in Q4 FY25, registering a growth of 9.17% as against Rs 883 crore reported in Q4 FY24. The operating EBITDA margin improved to 32.6% in Q4 FY25, up from 32.2% in the previous year. Torrent Pharmaceuticals reported India revenues of Rs 1,545 crore in Q4 FY25, marking a 12% year-on-year growth, driven by strong performance in focus therapies. According to AIOCD secondary market data, the Indian Pharmaceutical Market (IPM) grew 8% during the quarter. Torrent's chronic segment outpaced the market, posting a 14% growth compared to IPMs 9% rise in the same category. On a MAT (Moving Annual Total) basis, Torrent continued to outperform the industry across key therapy areas, supported by robust new product launches. The company currently has 21 brands ranked among the Top 500 in the IPM, with 14 brands clocking over Rs 100 crore in annual sales. Brazil revenues for Torrent Pharma stood at Rs 351 crore, marking a decline of 6%, primarily impacted by the steep depreciation of the Brazilian Real (BRL). However, constant currency revenues were $ 234 million, reflecting a 5% increase. The company also faced a challenge due to a lower-than-expected annual price increase on April 1st, which led wholesalers to reduce their inventory more than usual. According to IQVIA data, Torrent grew at 13%, outperforming the market's growth of 7%. Additionally, Torrent currently has sixty-three products under review by ANVISA. The company reported revenues of Rs 286 crore from its Germany operations in Q4 FY25, registering a 2% year-on-year growth. In constant currency terms, revenues stood at 31 million, up 1% YoY. The company attributed the modest growth to continued success in securing new tender wins, supported by ongoing cost improvement initiatives. Torrent Pharmaceuticals reported a 15% year-on-year rise in US business revenue at Rs 302 crore for Q4 FY25. In constant currency terms, revenue stood at $35 million, marking a 10% increase compared to the same period last year. On a full year basis, the companys net profit rallied 15.39% to Rs 1,911 crore on 7.34% rise in total revenue from operations to Rs 11,516 crore in FY25 over FY24. Torrent Pharmaceuticals reported strong performance in its India business for FY25, with revenues rising 13% year-on-year to Rs 6,393 crore. In Brazil, revenue declined 2% to Rs 1,100 crore; however, in constant currency terms, it grew 9% to R$734 million. The Germany business posted a 6% increase in revenue to Rs 1,139 crore, with constant currency growth of 5% at 126 million. Meanwhile, the US business recorded a 2% rise in revenue to Rs 1,100 crore. In constant currency, US revenue stood at $130 million, with flat growth of 1% after adjusting for one-off income in FY24. Meanwhile, the board recommended a final dividend of Rs 6 per equity share of Rs 5 each. Earlier an interim dividend of Rs 26 per equity share was paid during the last quarter, it added. Further, the board has approved the appointment of Aman Mehta as Managing Director, effective 1st August 2025. Lastly, the company said its board has recommended that members seek enabling approval to raise up to Rs 5,000 crore through the issuance of equity shares, including via convertible bonds/debentures, through qualified institutional placement (QIP) or any other modes at the upcoming annual general meeting. Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.
Economic Times
20-05-2025
- Business
- Economic Times
Torrent Pharmaceuticals Q4 Results: Net profit rises 11% to Rs 498 crore
Torrent Pharmaceuticals Ltd on Tuesday reported an 11 per cent rise in consolidated net profit at Rs 498 crore in the fourth quarter ended March 2025. The company, which had posted a consolidated net profit of Rs 449 crore in the corresponding quarter previous fiscal, announced the appointment of Aman Mehta -- elder son of Torrent Group Chairman Samir Mehta -- as Managing Director, effective August 1, 2025 as part of its succession planning. ADVERTISEMENT Consolidated total revenue from operations in the fourth quarter stood at Rs 2,959 crore as against Rs 2,745 crore in the same period a year ago, Torrent Pharmaceuticals Ltd said in a regulatory filing. Total expenses in the fourth quarter were higher at Rs 2,252 crore as compared to Rs 2,145 crore in the year-ago period, it added. During the quarter, the company said it had an exceptional item outgo of Rs 24 crore to settle a litigation over alleged price overcharging and demand raised by the National Pharmaceutical Pricing Authority (NPPA) in 2017. In the fourth quarter, India revenue was at Rs 1,545 crore, up 12 per cent led by outperformance in focus therapies. On the other hand, Brazil revenue was at Rs 351 crore, down 6 per cent, impacted by steep Brazilian Real (BRL) depreciation, it added. US business revenue was at Rs 302 crore, up by 15 per cent, and Germany revenue was up 2 per cent at Rs 286 crore, the company said. ADVERTISEMENT For fiscal 2024-25, consolidated net profit was at Rs 1,911 crore as against Rs 1,656 crore in 2023-24, the company said. FY25 consolidated total revenue from operations stood at Rs 11,516 crore as against Rs 10,728 crore in FY24, it added. ADVERTISEMENT Torrent Pharma said its board has recommended the members to obtain enabling approval to raise up to Rs 5,000 crore through issuance of equity shares, including via convertible bonds/debentures through Qualified Institutional Placement (QIP) and or any other modes in the upcoming Annual General Meeting. The board also recommended a final dividend of Rs 6 per equity share of Rs 5 each. Earlier an interim dividend of Rs 26 per equity share was paid during the last quarter, it added. (You can now subscribe to our ETMarkets WhatsApp channel)
Yahoo
19-05-2025
- Business
- Yahoo
Banco do Brasil SA BB Brasil (BDORY) Q1 2025 Earnings Call Highlights: Strong Financial ...
Release Date: May 16, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Banco do Brasil SA BB Brasil (BDORY) achieved a net income of BRL 7.4 billion in the first quarter, reflecting a strong financial performance. The bank has successfully launched a new product, Pledge to dotrabalaur, which significantly increased payroll loan agreements, achieving BRL 3 billion in disbursements in a short period. Banco do Brasil SA BB Brasil (BDORY) has maintained a strong relationship with over 86 million clients, leveraging CRM and AI to enhance customer interactions and insights. The bank has invested significantly in technology, with a 30% increase in tech investments compared to the previous year, enhancing client experience and security. Banco do Brasil SA BB Brasil (BDORY) continues to lead in ESG initiatives, being recognized as the most sustainable bank globally for the sixth consecutive year. The bank faced increased delinquency in the agribusiness segment, which was worse than expected, impacting financial results. New accounting regulations, specifically Resolution 4,966, have led to increased provisioning and impacted net interest income. The rise in interest rates has increased funding expenses, affecting the bank's net interest margin. The bank's profitability was impacted by a significant increase in provisions, particularly in the rural portfolio, which doubled compared to the previous quarter. There is ongoing uncertainty regarding the impact of new accounting rules and the agribusiness segment's performance, leading to a revision of financial guidance. Q: What has caused the worsening in delinquency KPIs across various segments, and what level of provisions can be expected for the next quarters? A: Prince, Head of Risk Management, explained that the transition to new models under Resolution 4,966 has led to a spike in delinquency, particularly in the individual segment. The corporate segment, especially SMEs, also showed worse performance. The agribusiness segment is facing challenges due to a record crop season but with delayed payments. Provisions are expected to remain under pressure in the short term, especially until the end of the crop season. Q: How is Banco do Brasil balancing capital and dividends amid uncertainties with agribusiness and new regulations? A: Giovanni, CFO, stated that the bank is maintaining a 40% payout and is focused on controlling delinquency, especially in agribusiness. Despite challenges, the bank has managed to improve its common equity and does not foresee any difficulty in growing its assets. The bank aims to sustain growth and maintain its payout ratio. Q: Why is there uncertainty in the NII guidance, and is there any risk to loan growth given the current asset quality issues? A: Giovanni, CFO, explained that the uncertainty is mainly due to new provisions under the central bank's regulation. The impact on NII was expected, but the magnitude of provision charges was greater than anticipated. The bank is focused on curbing delinquency in the agribusiness book and growing loans, particularly in the individual segment, to offset the impact of increased benchmark rates. Q: Why did Banco do Brasil experience a greater impact from the new accounting changes compared to its peers? A: Giovanni, CFO, noted that the bank's significant exposure to the agribusiness sector, which is not as prevalent among its peers, led to a greater impact. The rural portfolio accounted for a substantial portion of the provision charges, which doubled compared to the previous quarter. Q: How is Banco do Brasil addressing the challenges in the agribusiness segment, particularly with the increase in court reorganizations? A: Giovanni, CFO, and Prince, Head of Risk Management, highlighted that the bank is actively working to renegotiate debts and improve collection processes. The bank is focusing on maintaining seniority in payment flows and leveraging its capacity to manage risks better than competitors. The bank is also engaging with regulators to address the specificities of the agribusiness portfolio under the new accounting rules. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Americanas SA (BSP:AMER3) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Americanas SA (BSP:AMER3) reported a double-digit growth in same-store sales for the first four months of 2025, reflecting strong operational performance. The company successfully launched a new credit card in partnership with Brazil Car, aiming to issue 1 million cards within 12 months, enhancing customer loyalty and revenue. Americanas SA (BSP:AMER3) achieved a 14.2% growth in gross same-store sales in the first four months of 2025, driven by a strong Easter performance. The company has made significant progress in cost optimization, with a 10.9% reduction in SG&A expenses compared to the same period last year. Americanas SA (BSP:AMER3) is focusing on modernizing its technology infrastructure, which is expected to improve the shopping experience and operational efficiency. The financial results for Q1 2025 were negatively impacted by the timing mismatch of Easter, which occurred in Q2 instead of Q1. Gross profit and gross margin declined compared to the same period in 2024, partly due to extraordinary events that benefited the previous year's results. The company is still undergoing judicial recovery, which imposes certain restrictions and challenges on its operations. Americanas SA (BSP:AMER3) experienced a decline in the number of units sold during Easter due to higher chocolate prices and declining consumer purchasing power. The adjusted EBITDA for Q1 2025 was negative, reflecting the absence of Easter revenue in the quarter and extraordinary effects from the previous year. Warning! GuruFocus has detected 9 Warning Signs with BSP:AMER3. Q: Using the same adjustment for revenue, including Easter, would EBITDA have been positive? A: (CFO, Camil Ferrias) It's challenging to calculate precisely, but if we adjust for Easter, EBITDA for Q1 2025 would have been significantly better than Q1 2024. The difference of 150 million BRL could have been compensated by the Easter event, which generated 1.2 billion BRL in revenue. Thus, it's reasonable to estimate that EBITDA could have been positive. Q: What is Americanas' strategy to increase sales beyond seasonality? A: (CEO, Leonardo Coelho) While seasonality is inherent to our business, we are focusing on improving performance both during and outside of seasonal events. Initiatives like the new credit card and loyalty program, as well as expanding our product assortment, aim to enhance customer engagement year-round. Our goal is to simplify and improve the customer experience continuously. Q: When can we expect Americanas to exit judicial recovery? A: (CEO, Leonardo Coelho) We anticipate being under judicial recovery for two years. After fulfilling our obligations, the judge will evaluate our compliance. We expect to exit judicial recovery promptly, as we are on track with our debt payments and other commitments. Q: How does Americanas plan to handle the macroeconomic challenges affecting the retail sector? A: (CEO, Leonardo Coelho) We remain vigilant to macroeconomic impacts and are actively seeking ways to mitigate them. Our team has been exploring new business opportunities, including partnerships in China, to diversify and strengthen our operations. Q: Can you elaborate on the new credit card initiative? A: (COO, Fernando Soares) The new credit card, launched in partnership with Brazil Card, is a key part of our loyalty program. It offers benefits like interest-free installments and reward points. We aim to issue 1 million cards within 12 months to enhance customer loyalty and increase revenue. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
